Co.don (CNWK.DE) Osake Kurssi

Co.don AG is primarily active in the field of regenerative medicine.

Some of the main competitors of Co.don AG in the market include Arthrex, Smith & Nephew, and Medtronic.

Co.don AG is a German pharmaceutical company specializing in regenerative medicine. Established in 1993, Co.don AG has been dedicated to developing and providing innovative cell-based therapies for the treatment of articular cartilage damage and other orthopedic conditions. The company leverages its expertise in tissue engineering to produce autologous chondrocyte cultures, known as the Co.don Chondrosphere®. These personalized therapies allow patients to receive treatment using their own cells, enhancing the potential for successful cartilage repair and long-term improvement in joint function. With a strong commitment to research and development, Co.don AG continues to advance the field of regenerative medicine, contributing to the overall well-being and quality of life for patients worldwide.

Co.don AG, a leading biotechnology company, has achieved significant milestones in its history. It successfully developed and gained regulatory approval for its flagship product, the autologous cell-based therapy ChondroCelect®, which revolutionized the treatment of cartilage defects. This breakthrough therapy has provided effective and long-lasting solutions for patients suffering from knee cartilage damage. Co.don AG further expanded its presence by establishing collaborations with renowned medical institutions and key industry players, ensuring a wider reach for its innovative products and technologies. These milestones highlight Co.don AG's commitment to advancing regenerative medicine and improving patient outcomes in the field of orthopedics.

Co.don AG is primarily present in Germany and Europe.

Co.don AG represents values and a corporate philosophy centered around regenerative medicine and tissue engineering. As a leading expert in the field, Co.don AG is committed to providing innovative solutions for the repair and regeneration of damaged joint cartilage. With their advanced biotechnological processes, Co.don AG focuses on patient-specific cell therapies to improve quality of life. Their dedication to research, development, and manufacturing of these personalized treatments underscores their commitment to excellence in the field of regenerative medicine. By continuously pushing boundaries and emphasizing patient care, Co.don AG strives to be a global leader in providing effective and sustainable solutions for cartilage regeneration.

Co.don-osake (CNWK.DE) on listattuna 1 pörssissä, muun muassa: XETRA (CNWK.DE).

Co.don AG is a leading company in the field of regenerative medicine. Its main business is the development, production, and marketing of tissue replacement products for bone and cartilage repair. The company was founded in 1993 and is headquartered in Teltow near Berlin. Co.don AG operates in three business areas: tissue cultivation, device manufacturing, and distribution. In the tissue cultivation area, Co.don AG produces tissue replacement products that are grown from the patient's own cells. The patient's own tissue is collected, the necessary cells are isolated and cultivated in the laboratory. These cells are then used in special matrices to form the tissue replacement. The finished product is then administered to the patient to replace damaged or destroyed tissue. The company's main product in this area is ChondroGide. The second business area of the company is device manufacturing. Co.don AG produces the necessary devices and consumables for isolating the required cells and producing the tissue replacement. This includes bioreactors for cell cultivation and special matrices for cell proliferation. The main product in this area is BoneGide. The third business area of Co.don AG is distribution. The company distributes its products through a global network of sales partners. The company's customers are doctors and hospitals looking for innovative therapy options for their patients. Co.don AG works closely with its sales partners to ensure that the products are available worldwide. Co.don AG's business model is based on the development and marketing of innovative therapy options in the field of regenerative medicine. The company aims to offer products that help patients heal faster and return to their daily activities more quickly. Co.don AG conducts research to improve its products and develop new therapy options. The company has strong partnerships with research institutions around the world to ensure that it stays at the forefront of technology. With a strong focus on quality and safety, Co.don AG has achieved a leadership position in the field of regenerative medicine. The company aims to continue developing innovative therapy options and strengthen its position in the market. By selling tissue replacement products, devices, and consumables and collaborating with global sales partners, Co.don AG can meet the needs of its customers worldwide.

Liikevaihtoa ei voida laskea Co.don:lle tällä hetkellä.

Voittoa ei voida laskea Co.don:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Co.don:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Co.don:lle tällä hetkellä.

Co.don:n Eulpool-laatuscore on 6/10.

Co.don:n ISIN on DE000A1K0227. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Co.don:n WKN on A1K022. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Co.don:n ticker on CNWK.DE. Tämä pörssinoteeraus käytetään Co.don-osakkeiden kauppaan pörssissä.